SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
19.1 EUR
+0.46 (+2.47%)
We assign a fundamental rating of 6 out of 10 to 1SXP. 1SXP was compared to 19 industry peers in the Life Sciences Tools & Services industry. While 1SXP has a great profitability rating, there are some minor concerns on its financial health. 1SXP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year 1SXP was profitable.
In the past year 1SXP had a positive cash flow from operations.
In the past 5 years 1SXP has always been profitable.
In the past 5 years 1SXP always reported a positive cash flow from operatings.
1.2 Ratios
1SXP has a better Return On Assets (9.62%) than 94.74% of its industry peers.
With an excellent Return On Equity value of 17.03%, 1SXP belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
The Return On Invested Capital of 1SXP (13.86%) is better than 94.74% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1SXP is significantly above the industry average of 7.47%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.62% | ||
| ROE | 17.03% | ||
| ROIC | 13.86% |
ROA(3y)11.07%
ROA(5y)11.97%
ROE(3y)19.57%
ROE(5y)21.49%
ROIC(3y)15.67%
ROIC(5y)17.02%
1.3 Margins
With an excellent Profit Margin value of 15.07%, 1SXP belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
Looking at the Operating Margin, with a value of 19.41%, 1SXP belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
In the last couple of years the Operating Margin of 1SXP has grown nicely.
With a Gross Margin value of 33.73%, 1SXP is not doing good in the industry: 63.16% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.41% | ||
| PM (TTM) | 15.07% | ||
| GM | 33.73% |
OM growth 3Y4.06%
OM growth 5YN/A
PM growth 3Y0.29%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1SXP is creating value.
1SXP has more shares outstanding than it did 1 year ago.
1SXP has about the same debt/assets ratio as last year.
2.2 Solvency
The Debt to FCF ratio of 1SXP is 1.69, which is an excellent value as it means it would take 1SXP, only 1.69 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.69, 1SXP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 94.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | N/A |
ROIC/WACC1.68
WACC8.23%
2.3 Liquidity
1SXP has a Current Ratio of 1.57. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP's Current ratio of 1.57 is fine compared to the rest of the industry. 1SXP outperforms 78.95% of its industry peers.
A Quick Ratio of 1.16 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP has a better Quick ratio (1.16) than 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -3.00% in the last year.
1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.90% yearly.
1SXP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.86%.
1SXP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.84% yearly.
EPS 1Y (TTM)-3%
EPS 3Y13.9%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.13% on average per year.
The Revenue is expected to grow by 8.14% on average over the next years. This is quite good.
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.13%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y8.14%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
1SXP is valuated rather expensively with a Price/Earnings ratio of 19.69.
Based on the Price/Earnings ratio, 1SXP is valued a bit cheaper than the industry average as 78.95% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 25.98. 1SXP is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 16.33, which indicates a correct valuation of 1SXP.
78.95% of the companies in the same industry are more expensive than 1SXP, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 35.79. 1SXP is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.69 | ||
| Fwd PE | 16.33 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 78.95% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 56.4 | ||
| EV/EBITDA | 10.74 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)6.06
PEG (5Y)N/A
EPS Next 2Y8.71%
EPS Next 3Y10.5%
5. Dividend
5.1 Amount
With a yearly dividend of 0.87%, 1SXP is not a good candidate for dividend investing.
1SXP's Dividend Yield is a higher than the industry average which is at 0.73.
With a Dividend Yield of 0.87, 1SXP pays less dividend than the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.87% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
1SXP pays out 16.33% of its income as dividend. This is a sustainable payout ratio.
DP16.33%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
FRA:1SXP (11/26/2025, 5:29:52 PM)
19.1
+0.46 (+2.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.88B
Revenue(TTM)975.68M
Net Income(TTM)147.00M
Analysts78.95
Price Target29.58 (54.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.87% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.33%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.82%
PT rev (3m)-1.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.65%
EPS NY rev (3m)-1.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.61%
Revenue NY rev (1m)-0.3%
Revenue NY rev (3m)-1.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.69 | ||
| Fwd PE | 16.33 | ||
| P/S | 2.95 | ||
| P/FCF | 56.4 | ||
| P/OCF | 14.1 | ||
| P/B | 3.33 | ||
| P/tB | 3.45 | ||
| EV/EBITDA | 10.74 |
EPS(TTM)0.97
EY5.08%
EPS(NY)1.17
Fwd EY6.13%
FCF(TTM)0.34
FCFY1.77%
OCF(TTM)1.35
OCFY7.09%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)6.06
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.62% | ||
| ROE | 17.03% | ||
| ROCE | 16.98% | ||
| ROIC | 13.86% | ||
| ROICexc | 14.4% | ||
| ROICexgc | 14.81% | ||
| OM | 19.41% | ||
| PM (TTM) | 15.07% | ||
| GM | 33.73% | ||
| FCFM | 5.23% |
ROA(3y)11.07%
ROA(5y)11.97%
ROE(3y)19.57%
ROE(5y)21.49%
ROIC(3y)15.67%
ROIC(5y)17.02%
ROICexc(3y)16.17%
ROICexc(5y)17.75%
ROICexgc(3y)16.77%
ROICexgc(5y)18.76%
ROCE(3y)19.22%
ROCE(5y)20.88%
ROICexgc growth 3Y-8.55%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.4%
ROICexc growth 5YN/A
OM growth 3Y4.06%
OM growth 5YN/A
PM growth 3Y0.29%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 204% | ||
| Cap/Sales | 15.68% | ||
| Interest Coverage | 11.79 | ||
| Cash Conversion | 77.17% | ||
| Profit Quality | 34.69% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | N/A |
F-Score5
WACC8.23%
ROIC/WACC1.68
Cap/Depr(3y)291.66%
Cap/Depr(5y)279.8%
Cap/Sales(3y)17.76%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.94%
Profit Quality(5y)27.76%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y13.9%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.13%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y8.14%
EBIT growth 1Y11.76%
EBIT growth 3Y18.46%
EBIT growth 5YN/A
EBIT Next Year46.93%
EBIT Next 3Y24.15%
EBIT Next 5Y18.78%
FCF growth 1Y-26.72%
FCF growth 3Y33.53%
FCF growth 5YN/A
OCF growth 1Y-5.2%
OCF growth 3Y19.39%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 19.69 and the Price/Book (PB) ratio is 3.33.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 3 / 10 and the dividend payout ratio is 16.33%.